Bench to bedside

TRI is unique in Australia. Its focus is getting the benefits of medical research out to the community rapidly, efficiently and for the benefit of Australia and Australians. To achieve this, TRI first brings together the best researchers from four leading institutions: University of Queensland Diamantina Institute (UQDI), Queensland University of Technology Institute of Health and Biomedical Innovation (IHBI), Mater Research and the Princess Alexandra Hospital’s Centres for Research. 

With state-of-the-art technologies, overviewed and run by world experts, TRI researchers are at the forefront of their research fields. For example, TRI has the best gene sequencing technologies in the southern hemisphere, to track genetic causes of disease, led by Prof. Matt Brown.

An onsite contract manufacturing facility, run by world-leading Patheon, means outcomes of TRI’s research can be made and tested here in Australia. Incorporation of a biopharmaceutical manufacturing facility enables, in a single location, the discovery, manufacture and clinical testing of new treatments and vaccines.

TRI’s collective expertise focuses on discovering new therapies and vaccines to prevent and treat common and serious illnesses and diseases that affect the community-at-large with several in clinical trials. Prof Ranjeny Thomas and her team have developed a novel immunotherapy for rheumatoid arthritis.  This is coupled with Prof Frazer’s team currently trialling a vaccine to prevent herpes, and the  Australian Prostate Cancer Research Centre-Qld undertaking an international clinical trial to test the anti-cancer effect of a vitamin E-based compound on advanced stage prostate cancer patients.

Find out more about TRI’s Research.